Pyridoxamine improves functional, structural, and biochemical alterations of peritoneal membranes in uremic peritoneal dialysis rats

Kidney International

Volumn 68, Issue 3, 2005, Pages 1326-1336

  Kakuta, Takatoshi ^a   Tanaka, Reika ^b   Satoh, Yoshinobu ^b   Izuhara, Yuko ^b   Inagi, Reiko ^b   Nangaku, Masaomi ^b   Saito, Akira ^b   Miyata, Toshio ^b  

^a TOKAI UNIVERSITY   (Japan)

^b NONE

Author keywords

Advanced glycation end product; Angiogenesis; Carbonyl stress; Effective peritoneal surface area; Pentosidine; Ultrafiltration failure; Vascular endothelial growth factor

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CARBONYL DERIVATIVE; CYTOKINE; FIBROBLAST GROWTH FACTOR 2; PENTOSIDINE; PYRIDOXAMINE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; BLOOD; BLOOD VESSEL; CONTROLLED STUDY; DIALYSATE; FUNCTIONAL ASSESSMENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR BIOLOGY; NEPHRECTOMY; NONHUMAN; PERITONEAL DIALYSIS; PERITONEUM; PLASMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; STRUCTURE ANALYSIS; ULTRAFILTRATION; UPREGULATION; UREMIA;

ANIMALS; ARGININE; CREATININE; FIBROBLAST GROWTH FACTOR 2; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; LYSINE; MALE; NEPHRECTOMY; PERITONEAL DIALYSIS; PERITONEUM; PERITONITIS; PYRIDOXAMINE; RATS; RATS, SPRAGUE-DAWLEY; UREMIA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITAMIN B COMPLEX;

EID: 32644484516     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00531.x     Document Type: Article

References (48)

1. DAVIES SJ, PHILLIPS L, GRIFfiTH AM, et al: What really happens to people on long-term peritoneal dialysis? Kidney Int 54:2207-2217, 1998
2. KREDIET RT, BOESCOTEN EW, ZUYDERHOUND FMJ, ARISZ L: Peritoneal transport characteristics of water, low molecular weight solutes and proteins during long-term continuous ambulatory peritoneal dialysis. Perit Dial Bull 6:61-65, 1986
3. RIPPE B, KREDIET RT: Peritoneal physiology: Transport of solutes, in The Textbook of Peritoneal Dialysis, edited by Gokal R, Nolf KD, Dordrecht, The Netherlands, Kluwer Academic Publishers, 1994, pp 69-113
4. KREDIET RT: The peritoneal membrane in chlonic peritoneal dialysis. Kidney Int 55:341-356, 1999
5. KREDIET RT: Prevention and treatment of peritoneal dialysis membrane failure. Adv Ren Replace Ther 5:212-217, 1994
6. STRUIJK DG, KREDIET RT, KOOMEN GCM, et al: A prospective study of peritoneal transport in CAPD patients. Kidney Int 45:1739-1744, 1994
7. DAVIES SJ, BRYAN J, PHILLIPS L, RUSSEL GI: Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 11:448-506, 1996
8. COMBET S, FERRIER ML, VAN LANDSCHOOT M, et al: Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modifications in the peritoneum. J Am Soc Nephrol 12:2146-2157, 2001
9. KORBET SM, MAKITA Z, FIRANEK CA, VLASSARA H: Advanced glycosylation end products in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 22:588-591, 1993
10. MIYATA T, DEVYST O, KUROKAWA K, VAN YPERSELE DE STRIHOU C: Towards better dialysis compatibility: Advances in the biochemistry and pathophysiology of the peritoneal membranes. Kidney Int 61:375-386, 2002
11. NAKAYAMA M, KAWAGUCHI Y, YAMADA K, et al: Immunohistochemical detection of advanced glycosylation end products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 51:182-186, 1997
12. MIYATA T, HORIE K, UEDA Y, et al: Advanced glycation and lipoxidation of the peritoneal membrane: Respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 58:425-435, 2000
13. WITOWSKI J, KORYBALSKA K, WISNIEWSKA J, et al: Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Sac Nephrol 11:729-739, 2000
14. WIESLANDER A, FORSBACK G, SVENSSON E, LINDEN T: Cytotoxicity, pH, and glucose degradation products in 4 different brands of PD fluid. Adv Perit Dial 12:57-60, 1996
15. GARCIA-LOPEZ E, LINDHOLM B, TRANAEUS A: Biocompatibility of new peritoneal dialysis solutions: Clinical experience. Perit Dial Int 20 (Suppl 5):S48-S56, 2000
16. KREDIET RT, HO-DAC-PANNEKEET MM, IMHOLZ Al, et al: Icodextrin's effects on peritoneal transport. Perit Dial Int 17:35-41, 1997
17. FALLER B: Amino acid-based peritoneal dialysis solutions. Kidney Int 50 (Suppl 56):S81-S85, 1996
18. RIPPE B, SIMONSEN O, HEIMBURGER O, et al: Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 59:348-357, 2001
19. TOPLEY N: In vitro biocompatibility of bicarbonate-based peritoneal dialysis solutions. Perit Dial Int 17:42-47, 1997
20. FERIANI M, KIRCHGESSNER J, GRECA G, et al: Randomized long-term evaluation of bicarbonate-buffered CAPD solution. Kidney Int 54:1731-1738, 1998
21. LAGE C, PISCHETSRIDER M, AUFRICHT C, et al: First in vitro and in a dual-chambered bag. Perit Dial Int 20 (Suppl 5):S28-S32, 2000
22. PAPAPETROPOULOS A, GARCIA-CARDENA G, MADRI JA, SESSA WC: Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 100:3131-3139, 1997
23. VRIESE AS, TILTON RG, STEPHAN CC, LAMEIRE NH: Vascular endothelial growth factor is essential for hyperglycemia induced structural and functional alterations of the peritoneal membrane. J Am Soc Nephrol 12:1734-1741, 2001
24. MARGETTS PJ, KOLB M, GALT T, et al: Gene transfer of transforming growth factor-beta1 to the rat peritoneum: effects on membrane function. J Am Soc Nephrol 12:2029-2039, 2001
25. COMBET S, MIYATA T, MOULIN P, et al: Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis. J Am Soc Nephrol 11:717-728, 2000
26. OGATA S, YORIOKA N, KOHNO N: Glucose and predonisolone alter basic fibroblast growth factor expression in peritoneal mesothelial cells and fibroblasts. J Am Soc Nephrol 12:2787-2796, 2001
27. LAMEIRE N, VANBIESEN W, VAN LANDSCHOOT M, et al: Experimental models of in peritoneal dialysis: A European experience. Kidney Int 54:2194-2206, 1998
28. KLEINKNECHT C, TERZI F, BURTIN M, et al: Experimental models of nephron reduction: Some answers, many questions. Kidney Int 47 (Suppl 49):S51-S54, 1995
29. ZWEERS MM, SPLINT LJ, KREDIET RT, STRUJIK DG: Ultrastructure of basement membrane of peritoneal capillaries in a chronic peritoneal infusion model in the rat. Nephrol Dial Transplant 16:651-654, 2001
30. MIYATA T, UEDA Y, SHINZATO T, et al: Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: Renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 7:1198-1206, 1996
31. INAGI R, MIYATA T, YAMAMOTO T, et al: Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: Role in the functional and morphological alteration of peritoneal membranes in peritoneal dialysis. FEBS Lett 463:260-264, 1999
32. UEDA Y, MTYATA T, GOFFIN E, et al: Does removal of glucose lower the carbonyl stress of glucose containing peritoneal dialysis?: Effect of dwell time on carbonyl stress using icodextrin and amino acid peritoneal dialysis fluids. Kidney Int 58:2518-2524, 2000
33. ε-(carboxymethyl) lysine and imidazolones under conditions similar to continuous ambulatory peritoneal dialysis. Biochem Biophys Res Commun 280:1408-1414, 2001
34. ISHIKAWA N, MIYATA T, UEDA Y, et al: Affinity adsorption of glucose degradation products improves the biocompatibility of conventional peritoneal dialysis fluid. Kidney Int 63:331-339, 2003
35. BROWNLEE M, VLASSARA H, KOONEY T, et al: Aminoguanidine prevents diabetes-induced arterial wall protein crosslinking. Science 232:1629-1632, 1986
36. NAKAMURA S, MAKITA Z, ISHIKAWA S, et al: Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46:895-899, 1997
37. MIYATA T, UEDA Y, ASAHI K, et al: Mechanism of the inhibitory effect of OPB-9195 [(±)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5ylacetanilide] on advanced lipoxidation end product formation. J Am Soc Nephrol 11:1719-1725, 2000
38. LAMB EJ, CATELL WR, DAWNEY AB: In vitro formation of advanced glycation end products in peritoneal dialysis fluid. Kidney Int 47:1768-1774, 1995
39. AHKAND AA, KATO M, SUZUKI H, et al: Carbonyl compound crosslink cellular proteins and activate protein-tyrosine kinase p60c-src. J Cell Biochem 72:1-7, 1999
40. TAGUCHI T, SUGIURA M, HAMADA Y, MIWA I: Inhibition of advanced protein glycation by a Schiff base between aminoguanidine and pyridoxal. Eur J Pharmacol 378:283-289, 1999
41. BOOTH AA, KHALIFAH RG, HUDSON BG: Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: Comparison with aminoguanigine. Biochem Biophys Res Commun 220:113-119, 1996
42. KHALIFAR RG, BYNES JW, HUDSON BG: Amadorins: Novel post-amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 257:251-258, 1999
43. BOOTH AA, KHALIFAH RG, TODD P, HUDSON BG: In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs): Novel inhibition of post-amadori glycation pathways. J Biol Chem 272:5430-5437, 1997
44. ONORATO JM, JENKINES AJ, THORPE SR, BAYNES JW: Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. J Biol Chem 257:21177-21184, 2000
45. DEGENHARDT TP, ALDERSON NL, ARRINGTON DD, et al: Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61:930-950, 2002
46. NAGARAJ RH, SARKAR P, MALLY A, et al: Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: Characterization of a major product from the reaction of pyridoxamine and methylglyoxal. Arch Biochem Biophys 402:110-119, 2002
47. STIT A, GARDINER TA, ALDERSON NL, et al: The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51:2826-2832, 2002
48. ALDERSON NL, CHACHICH ME, YOSSEF NN, et al: The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int 63:2123-2133, 2003